These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 30045977)

  • 81. The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.
    Azeggagh S; Berwick DC
    Br J Pharmacol; 2022 Apr; 179(8):1478-1495. PubMed ID: 34050929
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.
    Batzu L; Urso D; Grothe MJ; Veréb D; Chaudhuri KR; Pereira JB
    Neurobiol Dis; 2023 Jul; 183():106182. PubMed ID: 37286171
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
    Chen J; Chen Y; Pu J
    Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Exploring the focal role of LRRK2 kinase in Parkinson's disease.
    Kumar S; Behl T; Sehgal A; Chigurupati S; Singh S; Mani V; Aldubayan M; Alhowail A; Kaur S; Bhatia S; Al-Harrasi A; Subramaniyan V; Fuloria S; Fuloria NK; Sekar M; Abdel Daim MM
    Environ Sci Pollut Res Int; 2022 May; 29(22):32368-32382. PubMed ID: 35147886
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Sanjari Moghaddam H; Aarabi MH
    Mov Disord; 2018 Dec; 33(12):1876. PubMed ID: 30452792
    [No Abstract]   [Full Text] [Related]  

  • 86. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.
    Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM
    J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients.
    Fernández B; Lara Ordóñez AJ; Fdez E; Mutez E; Comptdaer T; Leghay C; Kreisler A; Simonin C; Vandewynckel L; Defebvre L; Destée A; Bleuse S; Taymans JM; Chartier-Harlin MC; Hilfiker S
    Biochem J; 2019 Oct; 476(19):2797-2813. PubMed ID: 31527116
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Two Methods to Analyze LRRK2 Functions Under Lysosomal Stress: The Measurements of Cathepsin Release and Lysosomal Enlargement.
    Sakurai M; Kuwahara T
    Methods Mol Biol; 2021; 2322():63-72. PubMed ID: 34043193
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease.
    Taylor M; Alessi DR
    Curr Opin Cell Biol; 2020 Apr; 63():102-113. PubMed ID: 32036294
    [TBL] [Abstract][Full Text] [Related]  

  • 90. How Parkinson's Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types.
    Bailey HM; Cookson MR
    J Parkinsons Dis; 2024; 14(7):1331-1352. PubMed ID: 38905056
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.
    Chittoor-Vinod VG; Villalobos-Cantor S; Roshak H; Shea K; Abalde-Atristain L; Martin I
    J Neurosci; 2020 Aug; 40(32):6234-6249. PubMed ID: 32605938
    [TBL] [Abstract][Full Text] [Related]  

  • 92. LRRK2 Phosphorylation: Behind the Scenes.
    De Wit T; Baekelandt V; Lobbestael E
    Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.
    Qin Q; Zhi LT; Li XT; Yue ZY; Li GZ; Zhang H
    CNS Neurosci Ther; 2017 Feb; 23(2):162-173. PubMed ID: 27943591
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
    De Miranda BR; Castro SL; Rocha EM; Bodle CR; Johnson KE; Greenamyre JT
    Neurobiol Dis; 2021 Jun; 153():105312. PubMed ID: 33636387
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.
    Islam MS; Moore DJ
    Biochem Soc Trans; 2017 Feb; 45(1):163-172. PubMed ID: 28202670
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The unconventional G-protein cycle of LRRK2 and Roco proteins.
    Terheyden S; Nederveen-Schippers LM; Kortholt A
    Biochem Soc Trans; 2016 Dec; 44(6):1611-1616. PubMed ID: 27913669
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice.
    Zhao Y; Keshiya S; Atashrazm F; Gao J; Ittner LM; Alessi DR; Halliday GM; Fu Y; Dzamko N
    Neurobiol Dis; 2018 Dec; 120():76-87. PubMed ID: 30194047
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation.
    Kuwahara T; Funakawa K; Komori T; Sakurai M; Yoshii G; Eguchi T; Fukuda M; Iwatsubo T
    Neurobiol Dis; 2020 Nov; 145():105081. PubMed ID: 32919031
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Crystal structure of the WD40 domain dimer of LRRK2.
    Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.